IL203926A - Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses - Google Patents

Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses

Info

Publication number
IL203926A
IL203926A IL203926A IL20392610A IL203926A IL 203926 A IL203926 A IL 203926A IL 203926 A IL203926 A IL 203926A IL 20392610 A IL20392610 A IL 20392610A IL 203926 A IL203926 A IL 203926A
Authority
IL
Israel
Prior art keywords
benzothiazol
isoxazol
morpholin
imidazo
ethoxy
Prior art date
Application number
IL203926A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of IL203926A publication Critical patent/IL203926A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
IL203926A 2007-09-19 2010-02-11 Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses IL203926A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99463507P 2007-09-19 2007-09-19
PCT/US2008/010884 WO2009038757A2 (en) 2007-09-19 2008-09-19 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (1)

Publication Number Publication Date
IL203926A true IL203926A (en) 2016-02-29

Family

ID=40468693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL203926A IL203926A (en) 2007-09-19 2010-02-11 Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses

Country Status (20)

Country Link
US (2) US8883783B2 (enExample)
EP (1) EP2201018B1 (enExample)
JP (1) JP5462168B2 (enExample)
KR (2) KR101572701B1 (enExample)
CN (1) CN101868465B (enExample)
AR (1) AR068528A1 (enExample)
AU (1) AU2008302744B2 (enExample)
BR (1) BRPI0816904B8 (enExample)
CA (1) CA2696776C (enExample)
CY (1) CY1117583T1 (enExample)
DK (1) DK2201018T3 (enExample)
ES (1) ES2573292T3 (enExample)
HR (1) HRP20160520T1 (enExample)
HU (1) HUE027982T2 (enExample)
IL (1) IL203926A (enExample)
MX (1) MX2010002295A (enExample)
PL (1) PL2201018T3 (enExample)
SI (1) SI2201018T1 (enExample)
TW (1) TWI437988B (enExample)
WO (1) WO2009038757A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820657B2 (en) 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
PL2201018T3 (pl) 2007-09-19 2016-11-30 STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
AU2008325141B2 (en) * 2007-11-08 2014-03-20 Ambit Biosciences Corp. Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
JP6033678B2 (ja) 2009-03-23 2016-11-30 アムビト ビオスシエンセス コルポラチオン 併用療法を用いた治療方法
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
ES2605621T3 (es) * 2009-11-05 2017-03-15 Ambit Biosciences Corporation Procedimiento para la preparación de derivados de imidazo[2,1-b][1,3] benzotiazol
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
EP3652172B1 (en) * 2017-07-13 2021-08-25 Sunshine Lake Pharma Co., Ltd. Salt of substituted urea derivative and use thereof in medicine
CA3070104C (en) * 2017-07-18 2023-08-08 Agrimetis, Llc Methods for the purification of l-glufosinate and crystalline l-glufosinate ammonium forms
CN110763544A (zh) * 2019-09-20 2020-02-07 南京聚谱检测科技有限公司 一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) * 2020-02-20 2020-07-14 广东电科院能源技术有限责任公司 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (enExample) 1964-02-29
NL129626C (enExample) 1964-04-08
US3210370A (en) 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
JPS58109491A (ja) * 1981-12-23 1983-06-29 Yamanouchi Pharmaceut Co Ltd ２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体
US4464384A (en) 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ATE172975T1 (de) 1992-05-19 1998-11-15 Adir Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
JP3178843B2 (ja) 1995-03-13 2001-06-25 日研化学株式会社 イミダゾチアゾール化合物
WO1998006724A1 (en) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
ID26620A (id) 1997-12-22 2001-01-25 Bayer Ag Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU7887501A (en) 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003031587A2 (en) 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US20040127719A1 (en) 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
AU2003300800A1 (en) 2002-11-25 2004-06-18 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
JP2006516139A (ja) 2002-12-18 2006-06-22 マリンクロッド・インコーポレイテッド ヘテロアリールアセトアミド化合物の合成
KR100647583B1 (ko) 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
US20050197371A1 (en) 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
US7820657B2 (en) * 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
PL2201018T3 (pl) 2007-09-19 2016-11-30 STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
AU2008325141B2 (en) 2007-11-08 2014-03-20 Ambit Biosciences Corp. Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Also Published As

Publication number Publication date
ES2573292T9 (es) 2016-07-08
KR20100061734A (ko) 2010-06-08
AR068528A1 (es) 2009-11-18
JP2010539237A (ja) 2010-12-16
AU2008302744B2 (en) 2014-01-30
PL2201018T3 (pl) 2016-11-30
CA2696776A1 (en) 2009-03-26
US8883783B2 (en) 2014-11-11
CA2696776C (en) 2015-12-15
SI2201018T1 (sl) 2016-09-30
US20150238499A1 (en) 2015-08-27
ES2573292T3 (es) 2016-06-07
HRP20160520T1 (hr) 2016-07-29
EP2201018A2 (en) 2010-06-30
US20090131426A1 (en) 2009-05-21
BRPI0816904B1 (pt) 2021-08-10
CY1117583T1 (el) 2017-04-26
EP2201018B1 (en) 2016-03-16
CN101868465B (zh) 2013-12-25
TWI437988B (zh) 2014-05-21
MX2010002295A (es) 2010-03-22
TW200920360A (en) 2009-05-16
WO2009038757A2 (en) 2009-03-26
BRPI0816904A2 (pt) 2015-03-17
US9585892B2 (en) 2017-03-07
AU2008302744A1 (en) 2009-03-26
JP5462168B2 (ja) 2014-04-02
WO2009038757A3 (en) 2009-05-28
KR20150104231A (ko) 2015-09-14
CN101868465A (zh) 2010-10-20
KR101572701B1 (ko) 2015-11-27
DK2201018T3 (en) 2016-05-17
HUE027982T2 (en) 2016-11-28
BRPI0816904B8 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
IL203926A (en) Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses
SG10201401826TA (en) Formulation comprising metformin and vildagli ptin
IL190228A0 (en) Phenyl-and pyridyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
IL212308A0 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1] heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide and compositions comprising the same and uses thereof
PL2205244T3 (pl) Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych
EG25201A (en) 4-cyclopropyl-1,2,3- thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same
WO2007034196A3 (en) Imaging agents comprising silicon
LTPA2017031I1 (lt) 8-[{1-(3,5-Bis-(trifluormetil) fenil) -etoksi}-metil]-8-fenil-1,7-diaza-spiro[4.5]dekan-2-ono hidrochlorido druska ir jos gamybos būdas
IL185546A0 (en) N - (n - sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
IL192328A (en) Walls of yeast cells for the treatment and protection of plants against diseases caused by pathogenic factors and compounds containing these walls of yeast cells
NO20084270L (no) Anvendelse av imidazo[2,1-b] -1,3,4-tiadiazol-2-sulfonamidforbindelser for behandling av nevropatisk smerte
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
BRPI0810323A2 (pt) "combinação de ácido pirrolidona 5-carboxílico, uso do ácido pirrolidona 5-carboxílico, composição e seu uso"
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
EP1673384A4 (en) NITROSED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USE
WO2007110173A3 (de) Fungizide wirkstoffkombinationen
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
ZA201000987B (en) Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
WO2006124770A3 (en) Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
ZA200804732B (en) Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
DE60223086D1 (de) Modifikator für polymilchsäure und den modifikator enthaltende polymilchsäurezusammensetzung
WO2006091241A8 (en) Inorgano-neutralized calcined kaolins for use in silicone rubber-based formulations
ZA201004800B (en) Compound (r)-n*6*-ethyl-6,7-dihydro-5h-indeno(5,6-d)thiazole-2,6-diamine and the use as antipsychotics
WO2006122012A3 (en) Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed